Autoantibody targeting therapies in post COVID syndrome and myalgic encephalomyelitis/chronic fatigue syndrome, 2025, Wohlrab et al

Is it dangerous? It doesn't sound like a very attractive treatment to be on the receiving end of.

 

Apheresis can have serious unwanted effects. Shifts in fluid and blood clotting (more or less of it) can produce lethal effects. Like all these things it has got safer with familiarity and people being treated being generally fitter, but it is not free of dangers.

 

That's interesting. From the Dr Bhupesh Prusty pre-print paper.
Increased circulating fibronectin, depletion of natural IgM and heightened EBV, HSV-1 reactivation in ME/CFS and long COVID, 2023, Liu, Prusty et al

I wonder if the "Something in the Blood" study by Dr Audrey Ryback and @chillier are perhaps thinking thinking along the lines of Prusty's findings ..... can't wait until they report on their serum/muscle cell study..

 

If IgG only lasts 100 days, how would lowering it cause the sort of long term remissions that were reported in the cyclo trial?

Hypothetically speaking.

 

That is a tricky question. Cyclophosphamide was shown to be effective in rheumatoid arthritis but even with big doses the effect wore off completely by 3 months unless you repeated treatment.

The trouble with cyclophosphamide is that it has big effects on T cells as well (and other cells) so if it produces benefit we aren't much the wiser as to what the problem is.

 

Does Daratumumab also affect T cells etc? Or if that has a positive effect can we narrow down what is potentially being affected?

 

Shouldn't do because it binds to CD38, which is a 'label' on plasma cells and not that much else.
I daratumumab works we are talking about an antibody-dependent process. The trouble is that the error in behaviour might still be in a T cel population that gets signals via antibody binding.

 

Verry curious about your hypothesis. Please enlighten us

- are you referring to a downstream effect on T-cells?
- and/or the effect of antibodies depletion on the signaling of these antibodies?

 

Yes.

 

And the winner is???

So awful, having to wait for the answers

 

The Crowd : “give us some more…”